Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular iscalimab - CD40 inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Indication NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase Phase 2 Patients 260 Primary Outcome Measures Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Arms Intervention Three dose arms of CFZ533 Placebo Target Patients Patients with Sjögren's syndrome Readout Milestone(s) Publication 2022 2023 Oncology Appendix Abbreviations Other 72 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation